Please login to the form below

Not currently logged in

Keytruda hits survival targets in first-line kidney cancer

New data presented at ESMO congress


Merck & Co could steal the thunder of its German namesake Merck KGaA after reporting strong survival data for Keytruda in front-line renal cell carcinoma, the most common form of kidney cancer.

The US drugmaker – known as MSD outside North America – has just unveiled the results of its phase 3 KEYNOTE-426 trial of PD-1 inhibitor Keytruda (pembrolizumab) in combination with Pfizer’s VEGF-targeting Inlyta (axitinib), showing that the duo improved overall survival (OS) and progression-free survival (PFS) compared to Pfizer’s Sutent (sunitinib).

MSD says Keytruda is the first anti-PD-1 drug to improve both OS and PFS in first-line RCC, and that throws down a gauntlet to Merck and its partner Pfizer when it presents the JAVELIN Renal 101 study of its PD-1 drug Bavencio (avelumab) plus Inlyta in this cancer at the ESMO cancer conference this coming weekend.

Merck said in September that its trial met the PFS objective in the trial, which compares Bavencio and Inlyta to Inlyta alone, so all eyes will be on the ESMO presentation to see if it can also hit the OS endpoint.

In addition to “statistically significant and clinically meaningful” improvements on both survival measures, Keytruda plus Inlyta also achieved a higher overall response rate (ORR) compared to Sutent monotherapy, according to MSD, which said the improvements were “consistent regardless of PD-L1 expression and across all risk groups.”

Keytruda will now be filed for approval as a first-line RCC therapy alongside Inlyta, with the hope of providing a new treatment option for a patient group with poor prospects despite new targeted and immuno-oncology drugs. Fewer than 10% of people diagnosed with advanced RCC survive for five years, said MSD’s head of R&D Roger Perlmutter. “There is significant need for improved therapies for this disease,” he added.

Bristol-Myers Squibb’s cancer immunotherapy pairing of PD-1 inhibitor Opdivo (nivolumab) and CTLA4 inhibitor Yervoy (ipilimumab) was approved earlier this year as first-line treatment for RCC, but only in intermediate- and poor-risk patients. According to some oncologists this should now be considered the standard regimen for previously-untreated patients, so both the Keytruda and Bavencio trials are no longer using the correct control arm.

BMS is hoping to extend Opdivo’s use in first-line RCC via the TITAN study – looking at different regimens of Opdivo and Yervoy – and Roche is also eyeing the category with its IMmotion 151 study comparing PD-L1 inhibitor Tecentriq (atezolizumab) plus Avastin (bevacizumab) to Sutent, which showed positive effects on PFS at this year’s ASCO meeting.

Article by
Phil Taylor

25th October 2018

From: Marketing



Subscribe to our email news alerts

Featured jobs


Add my company
Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...

Latest intelligence

Animation: Living With
The journey from the patient's perspective...
Danny Buckland July2022
Achieving communication excellence by targeting the right channel at the right time
By Danny Buckland...
6 trends shaping the future of personalized medicine
Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....